Scancell Ltd is an innovative biotech company with facilities based at the Oxford Science Park and within the Biodiscovery Institute of the University of Nottingham.

Scancell is currently conducting a Phase 2 trial of its ImmunoBody® vaccine and also progressing to a first-in-human Phase 1/2 study of its Moditope® vaccine in patients with melanoma and advanced solid tumours, respectively. Scancell is also advancing its COVID-19 vaccine candidate to Phase 1 clinical trials.

There are no current vacancies.